• 1
    Albright F, Burnett CH, Smith PH, Parson W. Pseudohypoparathyroidism: an example of ‘Seabright-Bantam syndrome’. Endocrinology. 1942;30:92232.
  • 2
    Bastepe M. The GNAS locus and pseudohypoparathyroidism. Adv Exp Med Biol. 2008;626:2740.
  • 3
    Mantovani G, Spada A. Mutations in the Gs alpha gene causing hormone resistance. Best Pract Res Clin Endocrinol Metab. 2006;20:50113.
  • 4
    Kelsey C. Imprinting on chromosome 20: tissue-specific imprinting and imprinting mutations in the GNAS locus. Am J Med Genet C Semin Med Genet. 2010;154:37786.
  • 5
    Bastepe M, Frolich LF, Hendy GN, Indridason OS, Josse RG, Koshiyama H, Korkko J, Nakamoto JM, Rosenbloom AL, Slyper AH, Sugimoto T, Tsatsoulis A, Crawford JD, Juppner H. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest. 2003;112:125563.
  • 6
    Linglart A, Menguy C, Couvineau A, Auzan C, Gunes Y, Cancel M, Motte E, Pinto G, Chanson P, Bougneres P, Clauser E, Silve C. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med. 2011;364:221826.
  • 7
    Murray T, Rao LG, Wong MM, Waddell JP, McBroom R, Tam CS, Rosen F, Levine MA. Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. J Bone Miner Res. 1993;8:8391.
  • 8
    Usdin T, Hilton J, Vertesi T, Harta G, Segre G, Mezey E. Distribution of the parathyroid hormone 2 receptor in rat: Immunolocalization reveals expression by several endocrine cells. Endocrinology. 1999;140:336371.
  • 9
    Bagó A, Dimitrov E, Saunders R, Seress L, Palkovits M, Usdin TB, Dobolyi A. Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience. 2009;162:12847.
  • 10
    Isales C, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. 1991;129:48995.
  • 11
    Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab. 2001;280:E20913.
  • 12
    Resnick L, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78:38590.
  • 13
    Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:88493.
  • 14
    Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, Ayar A, Weryha G, Mirallie E. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009;146:103541.
  • 15
    Ferriss J, Brown JJ, Cumming AM, Fraser R, Lever AF, Peacock M, Robertson JI. Primary hyperparathyroidism associated with primary hyperaldosteronism. Acta Endocrinol (Copenh). 1983;103:36570.
  • 16
    Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi PG. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension. 2011;58:3416.
  • 17
    Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988;84:65460.
  • 18
    Zar JH. Biostatistical analysis. Englewood Cliffs, NJ: Prentice-Hall. 1984.
  • 19
    Arnaud CD, Tsao HS, Littledike T. Radioimmunoassay of human parathyroid hormone in serum. J Clin Invest. 1971;50:2134.
  • 20
    Pak C, Kaplan R, Bone H, Townsend J, Waters O. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med. 1975;292:497500.
  • 21
    Ellsworth R, Howard JE. Studies on the physiology of the parathyroid glands VII. Some responses of normal human kidneys and blood to intravenous parathyroid extract. Bull Johns Hopkins Hosp. 1934;54:296308.
  • 22
    Mallette L. Synthetic human parathyroid hormone (1–34) fragment for diagnostic testing. Ann Int Med. 1988;109:8004.
  • 23
    Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res. 1988;3:13344.
  • 24
    Zager PG, Hsueh WA, Luetscher JA, Biglieri EG, Dowdy AJ. Effect of des-Asp1 angiotensin II on secretion and metabolism of aldosterone. J Clin Endocrinol Metab. 1980;50:8748.
  • 25
    Portale AA, Lonergan ET, Tanney DM, Halloran BP. Aging alters calcium regulation of parathyroid hormone in healthy men. Am J Physiol. 1997;272:E13946.
  • 26
    Brent GA, Leboff MS, Seely EW, Conlin PR, Brown EM. Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans. J Clin Endocrinol Metab. 1988;67:94450.
  • 27
    Schwartz P, Sørensen HA, Transbøl I. Inter-relations between the calcium set-points of Parfitt and Brown in primary hyperparathyroidism: a sequential citrate and calcium clamp study. Eur J Clin Invest. 1994;24:5538.
  • 28
    Sbroochi AM, Rauch F, Lawson ML, Hadjiyannakis S, Lawrence S, Bastepe M, Jüppner H, Ward LM. Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis. Eur J Endocrinol. 2011;164:295301.
  • 29
    Kidd GS, Schaaf M, Adler RA, Lassman MN, Wray HL. Skeletal responsiveness in pseudohypoparathyroidism. A spectrum of clinical disease. Am J Med. 1980;68:77281.
  • 30
    Burnstein MI, Kottamasu SR, Pettifor JM, Sochett E, Ellis BI, Frame B. Metabolic bone disease in pseudohypoparathyroidism: radiologic features. Radiology. 1985;155:3516.
  • 31
    Kazama JJ, Suzuki K, Yokoseki A, Oyanagi A, Goto S, Shimada H, Maruyama H, Narita I, Gejyo F. Development of hungry bone syndrome after rapid lowering of PTH with intravenous maxacalcitol therapy in a patient with non-uremic secondary hyperparathyroidism. Clin Nephrol. 2003;60:36971.
  • 32
    Eubanks P, Stabile BE. A review of pseudohypoparathyroidism with insight into calcium homeostasis. Arch Surg. 1998;133:6736.
  • 33
    Tollin S, Perlmutter S, Aloia JF. Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type Ib. J Bone Miner Res. 2000;15:14126.
  • 34
    Breslau N, Moses AM, Pak CY. Evidence for bone remodeling but lack of calcium mobilization response to parathyroid hormone in pseudohypoparathyroidism. J Clin Endocrinol Metab. 1983;57:63844.
  • 35
    Hall F, Segall-Blank M, Genant HK, Kolb FO, Hawes LE. Pseudohypoparathyroidism presenting as renal osteodystrophy. Skeletal Radiol. 1981;6:436.
  • 36
    Mizunashi K, Furukawa Y, Sohn H, Miura R, Yumita S, Yoshinaga K. Heterogeneity of pseudohypoparathyroidism type I from the aspect of urinary excretion of calcium and serum levels of parathyroid hormone. Calcif Tissue Int. 1990;46:22732.
  • 37
    Kruse K, Kracht U, Wohlfart K, Kruse U. Biochemical markers of bone turnover, intact serum parathyroid hormone and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment. Eur J Pediatr. 1989;148:5359.
  • 38
    Yamamoto M, Takuwa Y, Masuko S, Ogata E. Effects of endogenous and exogenous parathyroid hormone on tubular reabsorption of calcium in pseudohypoparathyroidism. J Clin Endocrinol Metab. 1988;66:61825.
  • 39
    Aksnes L, Aarskog D. Effect of parathyroid hormone on 1,25-dihydroxyvitamin D formation in type 1 pseudohypoparathyroidism. J Clin Endocrinol Metab. 1980;51:12236.
  • 40
    Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS. Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab. 2012 Sep; 97(9):302530.
  • 41
    Schambelan M, Brust NL, Chang BC, Slater KL, Biglieri EG. Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism. J Clin Endocrinol Metab. 1976;43:11531.
  • 42
    Ganguly A, Dowdy AJ, Luetscher JA, Melada GA. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab. 1973;36:4014.
  • 43
    Shiroto H, Ando H, Ebitani I, Hara M, Numazawa K, Kawamura S, Sasaki H. Normotensive primary aldosteronism. Am J Med. 1980;69:6036.
  • 44
    Kono T, Ikeda F, Oseko F, Imura H, Tanimura H. Normotensive primary aldosteronism: report of a case. J Clin Endocrinol Metab. 1981;52:100913.
  • 45
    Matsunaga M, Hara A, Song TS, Hashimoto M, Tamori S, Ogawa K, Morimoto K, Pak CH, Kawai C, Yoshida O. Asymptomatic normotensive primary aldosteronism. Case report. Hypertension. 1983;5:2403.
  • 46
    Llach F, Weidmann P, Reinhart R, Maxwell MH, Coburn JW, Massry SG. Effect of acute and long-standing hypocalcemia on blood pressure and plasma renin activity in man. J Clin Endocrinol Metab. 1974;38:8417.
  • 47
    Shackney S, Hasson J. Precipitous fall in serum calcium, hypotension, and acute renal failure after intravenous phosphate therapy for hypercalcemia. Ann Int Med. 1967;66:90616.
  • 48
    Seifen E, Flacke W, Alper MH. Effects of calcium on isolated mammalian heart. Am J Physiol. 1964;207:71620.
  • 49
    Friedman PA. Codependence of renal calcium and sodium transport. Annu Rev Physiol. 1998;60:17997.
  • 50
    Adam WR, Koretsky AP, Weiner MW. 31P-NMR in vivo measurement of renal intracellular pH: effects of acidosis and K+ depletion in rats. Am J Physiol. 1986;251:F90410.
  • 51
    Velazquez H, Bartiss A, Bernstein P, Ellison DH. Adrenal steroids stimulate thiazide-sensitive NaCl transport by rat renal distal tubules. Am J Physiol. 1996;270:F2119.